Chondroitin sulfate is almost always sold alongside glucosamine, but it has its own research history, its own animal sources, and a regulatory position worth knowing: in Japan and in parts of Europe it is also used as a medicine, not only as a food ingredient. Brands abroad ask for a Japan-made chondroitin product without always knowing that difference exists.
This guide is for brand owners planning a Japan-made chondroitin product. It covers what the trial evidence actually shows, where chondroitin is treated as a medicine, its animal sources, and what to fix before a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a chondroitin product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 2015 Cochrane review found a small short-term pain benefit from chondroitin in people with osteoarthritis, but the benefit became uncertain when the analysis was limited to larger trials, trials with adequate allocation concealment or trials without pharmaceutical funding.
| Study | Design/What was analysed | Reported result |
|---|---|---|
| Cochrane systematic review, Cochrane Database of Systematic Reviews 2015 (PMID 25629804) | 43 randomised trials of chondroitin, alone or with glucosamine, in people with osteoarthritis (mostly knee); 4,962 participants on chondroitin and 4,148 controls | In mostly low-quality trials, chondroitin improved pain slightly more than placebo in short-term studies (8 points on a 0–100 scale) and slightly reduced loss of joint-space width, with adverse events similar to comparators. The benefit persisted in trials with adequate blinding or intention-to-treat analysis, but was uncertain in trials with adequate allocation concealment, more than 200 participants or no pharmaceutical funding |
| Randomised, placebo- and celecoxib-controlled trial — GAIT, New England Journal of Medicine 2006 (PMID 16495392) | 1,583 patients with symptomatic knee osteoarthritis; chondroitin sulfate 1,200 mg/day, glucosamine, the combination, celecoxib or placebo for 24 weeks | Chondroitin sulfate alone did not significantly reduce knee pain in the overall group versus placebo |
| Network meta-analysis, BMJ 2010, 341:c4675 (PMID 20847017, PMC2941572) | 10 randomised trials, 3,803 patients with hip or knee osteoarthritis | The difference from placebo for chondroitin was −0.3 cm on a 10 cm pain scale, short of the pre-specified minimal clinically important difference of −0.9 cm; industry-independent trials showed smaller effects than commercially funded trials |
| Randomised, double-blind, placebo- and celecoxib-controlled trial — CONCEPT, Annals of the Rheumatic Diseases 2017, 76(9):1537–1543 (PMID 28533290, PMC5561371) | 604 patients with knee osteoarthritis in five European countries; pharmaceutical-grade chondroitin sulfate 800 mg/day, celecoxib or placebo for 6 months | Chondroitin sulfate reduced pain and improved function more than placebo, similar to celecoxib; the trial was sponsored by a pharmaceutical company that markets chondroitin sulfate |
Caveats to keep in view:
- Population. All four studies were conducted in people already diagnosed with osteoarthritis — a disease population. That belongs in the research table, never in a product claim.
- Trial quality and funding shape the result. The Cochrane benefit held in adequately blinded trials but became uncertain in larger trials, trials with adequate allocation concealment and trials without pharmaceutical funding, and the BMJ analysis found smaller effects in industry-independent trials. The positive CONCEPT result came from a company-sponsored trial of one pharmaceutical-grade product. That pattern is the single most important honesty point for this ingredient.
- Chondroitin is usually tested combined with glucosamine, which makes it hard to separate chondroitin’s own contribution from the combination’s effect in some of the literature.
Checked against the published abstracts on 13 October 2026.
What Japanese products say
In Japan, chondroitin sulfate can be used in foods, but it is also the active ingredient of prescription and over-the-counter medicines, so a food product must stay clear of medicinal claims and medicinal amounts.
Chondroitin sulfate is on the Ministry of Health, Labour and Welfare’s (MHLW) list of substances not treated as medicines unless medicinal claims are made, so it can be used as a food ingredient, and sodium chondroitin sulfate is a designated food additive. At the same time, sodium chondroitin sulfate is the active ingredient of a prescription medicine listed by the Pharmaceuticals and Medical Devices Agency (PMDA), with indications including joint pain and lower back pain at 0.3–1.2 g three times a day, and of third-class over-the-counter medicines that combine it with vitamin B1. MHLW has long guided that when a health-food ingredient is also used as an oral medicine, the food should not exceed the amount used as a medicine.
In Japanese joint products, chondroitin is most often combined with glucosamine. If your brand wants a specific functional claim in Japan for a chondroitin-containing product, the evidence would need to be prepared and notified under Foods with Function Claims for your own formula.
Outside Japan, chondroitin’s status also varies. In parts of Europe, prescription formulations of chondroitin sulfate are used as medicines and classed among symptomatic slow-acting drugs for osteoarthritis; the CONCEPT trial above tested such a pharmaceutical-grade product against a European Medicines Agency guideline for medicines.
This matters for a brand abroad in a very practical way: the same ingredient can be a food supplement in one country and a regulated medicine in another. Before you commit to a market, confirm chondroitin’s status there — a product legal to sell as a food supplement in Japan or your home market may need a medicine licence, or may not be sellable at all as a supplement, elsewhere.
💬 Need help checking whether chondroitin is food-supplement-eligible in your target market? Tell us your markets and we will flag what to confirm with your local regulatory adviser.
Wording that stays on safe ground
Describe chondroitin by what was studied — joint comfort in people already managing osteoarthritis — and be explicit that larger and independent trials found weaker or uncertain results; never promise pain relief or joint repair.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for knee joint comfort" | "Treats osteoarthritis”, “rebuilds cartilage”, “stops joint pain" |
| "Contains chondroitin sulfate” with the amount and source per serving | Citing the Cochrane review’s small positive result without also noting its own caveat about trial quality |
| Naming the study, its population and its actual result if you reference research at all | ”Clinically proven” without naming the study and what it actually found |
How chondroitin is formulated
Chondroitin sulfate is a gram-level daily ingredient, usually supplied as a powder for tablets, capsules or drink sticks, and its animal source is a specification decision, not a formality.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Tablet | Standard for gram-level daily doses, easy to combine with glucosamine | Tablet size and number needed per day |
| Hard capsule | Flavourless, simple to combine with other joint ingredients | More capsules needed per gram-level dose |
| Powder stick or drink mix | Familiar Japanese joint-health format, suits combination with glucosamine | Chondroitin can affect mouthfeel/viscosity in drinks |
Decisions that shape the specification:
- Animal source. Chondroitin sulfate for supplements is extracted from cartilage — commonly shark cartilage, salmon (fish) cartilage, or bovine and porcine (cattle and pig) trachea or nasal cartilage, depending on the supplier. The source affects religious and dietary suitability (halal, kosher, vegetarian exclusions), sustainability positioning, and in some markets the allergen or BSE-related sourcing questions buyers raise. Confirm the exact species and tissue with your supplier; do not assume “chondroitin” means one single source.
- Molecular weight and purity. Chondroitin sulfate specifications vary by source and manufacturing process. Ask the supplier for its specification sheet and purity grade.
- Amount per serving. Match the amount to the trial you intend to reference; the large independent trials above used chondroitin sulfate at doses that still did not clear the threshold for clinical relevance overall, so avoid implying a guaranteed effect at any dose. For Japan, also keep the daily amount below the amount used in chondroitin medicines.
- Companion ingredients and market status. Glucosamine, MSM and collagen are common partners. Confirm chondroitin’s own regulatory status — food supplement or medicine — in every country you plan to sell in, separately from checking the companion ingredients.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Chondroitin sulfate is on Japan’s list of substances usable in foods, but because it is also a medicine ingredient in Japan and in parts of Europe, medicinal claims and medicinal amounts must be avoided, and its status in each export market is one of the first questions to settle. See the Japan-made supplement OEM page, and our glucosamine guide if you are planning a combined joint product.
Before you ask for a quotation
A factory can quote accurately once the animal source, the amount, the market status and the packaging are fixed.
- Chondroitin sulfate animal source (shark, salmon, bovine, porcine) and specification
- Amount per serving and dosage form
- Companion ingredients and their amounts
- Confirmed regulatory status (food supplement or medicine) in each target market
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made chondroitin product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does chondroitin work for joint pain?
A 2015 Cochrane review of mostly low-quality trials found a small short-term pain benefit. It held in adequately blinded trials but became uncertain in larger trials, trials with adequate allocation concealment and trials without pharmaceutical funding. GAIT and a 2010 BMJ network meta-analysis found no benefit reaching the threshold for clinical relevance, while a company-sponsored European trial of a pharmaceutical-grade product reported a benefit over placebo. Describe chondroitin as studied for joint comfort, not as a proven pain treatment.
2. Is chondroitin a food supplement or a medicine?
It depends on the market, and in Japan it is both. Chondroitin sulfate can be used in Japanese foods, while sodium chondroitin sulfate is also the active ingredient of prescription and over-the-counter medicines there. In parts of Europe, prescription formulations are used as medicines. Confirm chondroitin’s status in every market before you commit to a formula.
3. What animal is chondroitin from?
Commonly shark cartilage, salmon (fish) cartilage, or bovine or porcine (cattle or pig) trachea and nasal cartilage, depending on the supplier. Always confirm the exact species and tissue for religious, dietary and sustainability positioning.
4. Why is chondroitin almost always paired with glucosamine?
Most of the major trials tested them together, and Japanese and international joint products follow that convention. It also makes it harder to separate chondroitin’s own contribution from the combination’s effect in some of the research.
5. What can stop a Japanese factory making my chondroitin product?
Usually confirming the animal source meets your market’s dietary requirements, or confirming chondroitin’s own regulatory status where you plan to sell. Every ingredient must be permitted in foods in Japan, so we check the full formula first.
Sources: “Chondroitin for osteoarthritis”, Cochrane Database of Systematic Reviews 2015, CD005614 (PMID 25629804, PMC4881293); “Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis”, New England Journal of Medicine 2006, 354(8):795-808 (PMID 16495392); “Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis”, BMJ 2010, 341:c4675 (PMID 20847017, PMC2941572); “Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)”, Annals of the Rheumatic Diseases 2017, 76(9):1537-1543 (PMID 28533290, PMC5561371); MHLW list of substances not treated as medicines unless medicinal claims are made (Annex 2, updated 5 August 2026); MHLW notice Shokuan-Kihatsu No. 1105001 (5 November 2004), note 4 on sodium chondroitin sulfate as a designated additive; MHLW press release of 22 August 2005 on health-food ingredients also used as oral medicines; PMDA package inserts for a prescription sodium chondroitin sulfate tablet and a third-class over-the-counter medicine containing sodium chondroitin sulfate. Checked on 13 October 2026.